We are here to bring genomics
into everyday care
MEET OUR FOUNDERS
Lisa has 20 years of experience building early-stage companies with a focus on technology, consumer and life sciences businesses. Prior to Genome Medical, Lisa served as the chief commercial officer and chief strategy officer of Invitae (NYSE: NVTA), a rapidly growing genetic information company. She was part of the start-up team at Genomic Health Inc. (Nasdaq: GHDX), president of Cinema Circle, Inc., and the former manager of strategic planning at The Walt Disney Co.
Randy is a co-founder and chairman at Genome Medical. He was formerly the chairman of Invitae, a company he co-founded and where he previously served as CEO. He also founded Genomic Health and served as Genomic Health’s chief executive officer from 2000 until 2009 and executive chairman until 2012. Under Randy’s leadership, Genomic Health developed and launched two revolutionary cancer diagnostic tests. At Incyte, Randy served in various roles from 1991 through 2000, including chairman of the board, president and chief scientific officer.
Dr. Green is co-founder and chairman of Genome Medical’s Scientific Advisory Board. He is a medical geneticist and physician-scientist who directs the G2P Research Program in translational genomics and health outcomes in the Division of Genetics at Brigham and Women’s Hospital and Harvard Medical School. Dr. Green is principal investigator of the MedSeq Project, the first NIH-funded randomized trial to explore the use of whole genome sequencing in the clinical practice of medicine.
”Genome Medical is a mission-driven organization bringing genomic medicine to everyday care. We are delivering the future of health care today through our nationwide network of clinical genetic experts and our efficient genomic care delivery platform. Our team is dedicated to improving patient health and reducing the cost of health care delivery.Lisa AldersonCo-Founder and Chief Executive Officer
Steven Bleyl, MD, PhD
Steve is Genome Medical’s chief medical officer. He is a board-certified medical geneticist and associate professor in medical genetics and pediatrics at the University of Utah. Previously, Steve directed the Clinical Genetics Institute for Intermountain Healthcare in Salt Lake City.
Erynn Gordon, MS, LCGC
Erynn is a board-certified genetic counselor with expertise in clinical care, research and laboratory genetics. A leader in the genetic counseling community, Erynn has served as president of the American Board of Genetic Counseling and on the National Society of Genetic Counselors board of directors. Prior to joining Genome Medical, Erynn was the first genetic counselor at 23andMe, serving as director of clinical affairs. She previously managed a precision medicine study at at the Coriell Institute for Medical Research and held clinical roles at the University of Maryland School of Medicine and Children’s National Medical Center.
Alan Rope, MD
Alan is Genome Medical’s pediatric genetics lead. He previously served as a staff physician and medical geneticist at Kaiser Permanente Northwest and as an associate clinical professor of pediatrics at the University of Utah School of Medicine.
Scott Weissman, MS, LCGC
Scott serves as Genome Medical’s cancer service lead. He is a board-certified genetic counselor with 15+ years experience in adult-onset genetic disorders and a focus on cancer genetics. He has worked at several hospitals as well as genetic testing labs.
Betsy Swope, MS, CGC
Betsy is Genome Medical’s reproductive service lead. She is a board-certified genetic counselor with more than 17 years of experience. She has worked at the University of Michigan, the University of North Carolina and Progenity, Inc.
Lindsay Meyers, MS, LCGC
Lindsay is Genome Medical’s cardiovascular service lead. She is a board-certified genetic counselor specializing in cardiac and pediatric genetics. She has over 9 years of experience and helped establish the first genetics service in pediatric cardiology at Primary Children’s Hospital.
MEDICAL AND SCIENTIFIC AFFAIRS TEAM
Hunt Willard, PhD
Hunt has deep experience in genetics and genomics leadership in academia, health care and industry, building teams that span research, education and clinical care. Prior to joining Genome Medical, he was most recently director and principal of National Precision Health at Geisinger Health in Maryland and Pennsylvania, with a focus on design and implementation of large-scale clinical and research programs in genomics and population screening. He is the author or co-author of more than 350 scientific publications, co-editor of the Genomic and Precision Medicine book series and a longtime co-author of the textbook Genetics in Medicine. A former president of the American Society of Human Genetics, he is an elected member of the National Academy of Medicine and the National Academy of Sciences.
Erica Ramos, MS, CGC
Erica is the vice president of population genomics at Genome Medical. She is responsible for developing the strategy, value proposition and overall approach to population-scale health initiatives utilizing genetics and genomics and is passionate about establishing genomics as a resource for life-long care and integrating broad-based screening approaches with indication-based diagnostic services. In her previous role as director of clinical and product development at Geisinger National Precision Health, she and her team developed and integrated scalable, efficient and innovative clinical programs and products to accelerate the responsible adoption and integration of genomics into preventive care and population health. Prior to joining Geisinger, Erica was an associate director of market development for Precision Health and Screening at Illumina and practiced as a clinical genetic counselor for 11 years. Erica is a nationally recognized leader in the genetic counseling community, serving as the 2018 president of the National Society of Genetic Counselors, the leading professional organization for genetic counselors, more than 4,000 members strong, and serving on the All of Us Research Program Advisory Panel. She is also an adjunct professor in the Genetic Counseling Department at Augustana University and shares her enthusiasm for genomics, genetic counseling and Wisconsin sports on Twitter at @ERamosSD.
Beth Denne, MS, CGC
Beth is a board-certified and licensed genetic counselor, practicing since 2000. A leader in the genetic counseling community, Beth has served as president of the American Board of Genetic Counseling and on several committees for the National Society of Genetic Counselors. Prior to joining Genome Medical, Beth was the genetic counseling and education program leader for Geisinger National Precision Health. She previously served as director of genetic counseling services for Counsyl, Inc. During her seven years at Counsyl, she helped to develop and build the genetic counseling service, which incorporated new technologies and alternative service delivery models for telegenetic counseling into standard practice. Beth spent the first 12 years of her career at Johns Hopkins University Hospital as a Gyn/Ob faculty member in the Department of Maternal-Fetal Medicine.
Lisa has 20 years of experience building early-stage companies with a focus on technology, consumer and life sciences businesses. Prior to Genome Medical, Lisa served as the chief commercial officer and chief strategy officer of Invitae (NYSE: NVTA), a rapidly growing genetic information company. She was part of the start-up team at Genome Health Inc. (Nasdaq: GHDX), president of Cinema Circle, Inc., and the former manager of strategic planning at The Walt Disney Co.
Amy brings decades of experience in business development and commercialization to her position at Genome Medical, where she oversees sales, business development, marketing and managed care. She recently served as senior vice president of business development for Vituity, a leader in providing acute care management and medical staffing services. She previously held leadership positions with The Advisory Board Company, Advogent (formerly Cardinal Health) and Corporate Executive Board. She received her masters of business administration from Georgetown University and her bachelor’s degree from Cornell University.
After receiving her MBA from UCLA’s Anderson School of Management, Kristin worked in leadership capacities at DaVita and Counsyl. Most recently, she has been the senior vice president of business operations at MyHealthTeams, where she worked alongside the co-founders to drive corporate and functional strategy and deliver recognized revenue through client-based projects.
James is a product leader with experience in several start-ups in digital health and medical devices. He has held several roles at the Boston Consulting Group, including project leader with health care and life sciences clients and senior product manager in BCG Digital Ventures, a digital innovation, product development and commercialization firm. Outside of work, James has served at several non-profits supporting at-risk youth, including Peninsula Bridge, Big Brothers Big Sisters and One Hope United. He holds a bachelor’s degree in mechatronics from the University of Auckland and an MBA from the Stanford University Graduate School of Business.
Vineet is a seasoned Silicon Valley engineering leader with 20 years of building high-performing teams and products. His domain expertise ranges from search engines, storage appliances, network security and cloud computing to cybersecurity and AI. He has a successful track record in taking engineering-driven start-ups through IPO (Fireeye) and acquisition (Cisco/Virtuata). Building engineering teams from the ground up and then scaling them geographically and functionally to meet growing customer demands are recurrent themes in his career.
After receiving her law degree from the UCLA School of Law, Minh worked in private practice before taking on leadership roles at health care companies and labs, including Myriad Genetics, Counsyl and McKesson. Recently, Minh served as associate general counsel, global head of litigation and employment of Myriad and division general counsel of the Myriad AutoImmune business. She worked with and supported executive leadership, providing legal advice and guidance on various matters, including health care regulatory issues, compliance, policy, commercial and IP strategy.
Angie has more than 25 years of experience in sales, business development and health care management. Before joining Genome Medical, she served as vice president of channel and business development at the clinical communications company TigerConnect. Previously, she directed enterprise sales at Picis Clinical Solutions and was a senior sales executive at Athenahealth.
Josh has more than 15 years in sales leadership roles working with health systems, payers and PBMs nationally. Most recently, he was vice president of sales at Forward Health Group. He previously held sales leadership positions at Becton Dickinson within their data mining and clinical surveillance business unit and DrFirst’s patient innovation division. He holds an undergraduate degree from the University of Wisconsin-Madison and an MBA from DePaul’s Kellstadt School of Business.
Michael has more than 25 years of experience in sales and business development within the digital health benefits and population health management industries. He has broad expertise in both the large employer and payer markets with a focus on driving business through the development of customer relationships in new markets. Before joining Genome Medical, he served as vice president of client revenue at Context 4 Healthcare, an industry leader in developing health care compliance solutions. Prior to Context, Michael held several positions within the population management health industry.
Lisa has 20 years of experience in the genomics industry. She began her career as an account executive with Myriad Genetics before moving up through the ranks of other commercial genomics laboratories such as Athena Diagnostics, Genoptix and Lineagen and joining the leadership team at InformedDNA. Most recently, Lisa was the vice president of commercialization at PierianDx, where she helped build and grow their precision medicine programs and offerings.
Bill has worked in health care communications and marketing for more than 20 years. He joined Genome Medical from 23andMe, where he was the senior manager for commercial marketing. Previously, Bill worked at ZEISS Medical Technology on the global communications team, and he also served as director of communications at the American Academy of Ophthalmology.
Louis is a highly accomplished, outcomes-driven managed markets manager with an extensive background in medical policy, reimbursement and sales leadership within women’s health, oncology and biotech arenas. He has a proven track record of negotiating favorable medical policy changes among numerous payors and negotiating solid contracts in numerous payor environments, including HMOs, TPAs, IPAs, LBMs and IDNs.
SCIENTIFIC ADVISORY BOARD
Robert Green, MD, MPH
Robert is a professor of medicine at Harvard Medical School and directs the Genomes2People Research Program in translational genomics at Brigham and Women’s Hospital and Broad Institute. He conducts empirical research on the medical, behavioral and economic outcomes around the implementation of genomic medicine. Dr. Green is directing some of the first trials to explore sequencing in adults (the MedSeq Project) newborn infants (the BabySeq Project) and active-duty military personnel (the MilSeq Project).
Gerard T. Berry, MD
Gerard is director of the Metabolism Program at Children’s Hospital Boston, a professor of pediatrics at Harvard Medical School and director of Harvard’s Biochemical Genetics Training Program. A leader in metabolic genetics, he is 2019 president-elect of the Society of Inherited Metabolic Disorders.
Heather Hampel, MS, LCGC
Heather is an associate director of the Division of Human Genetics, associate director of biospecimen research at The Ohio State University Comprehensive Cancer Center and former president of the American Board of Genetic Counseling. Ms. Hampel is an internationally recognized cancer genetic counselor whose research has led to changes in standard-of-care genetic screening practices for colon cancer.
Bruce R. Korf, MD, PHD
Dr. Korf is Associate Dean for Genomic Medicine and Chief Genomics Officer at University of Alabama at Birmingham, and co-directs the UAB-HudsonAlpha Center for Genomic Medicine. He is current president of the American College of Medical Genetics and Genomics Foundation for Genetic and Genomic Medicine and has held leadership roles in most of the major genetics professional societies. In addition, Dr. Korf is at the forefront of developing novel approaches for integrating genetics and genomics into medical practice.
Robert L. Nussbaum, MD
Robert is chief medical officer of Invitae. He is the former chief of the University of California, San Francisco’s Division of Genomic Medicine, and medical director of the Cancer Risk Program and the UCSF Program in Cardiovascular Genetics. He is also the former chief of the Genetic Diseases Research and Inherited Disease Research Branches of the National Human Genome Research Institute and former president of the American Society of Human Genetics.
Heidi L. Rehm, PhD, FACMG
Heidi is director of the Partners Healthcare Laboratory for Molecular Medicine, medical director of the Broad Institute’s Clinical Research Sequencing Platform and associate professor of pathology at Brigham and Women’s Hospital and Harvard Medical School. Through her leadership roles in the NIH-funded Clinical Genome Resource Program and the International Global Alliance for Genomics and Health as well as committee roles in the American College of Medical Genetics and Genomics, she has been instrumental in developing standards and resources to support data sharing, genomic sequencing and the interpretation of genetic variation.
Jacquelyn Taylor, PhD, RN
Jacquelyn is associate professor and Vernice D. Ferguson Chair in Health Equity at the Rory Meyers College of Nursing, New York University. Her work examines genomic and social factors contributing to health disparities for chronic conditions in underrepresented populations. In 2017, she was awarded the Presidential Early Career Award for Scientists and Engineers by President Obama.
Sharon F. Terry, MA
Sharon is president and CEO of Genetic Alliance and co-founder of the Genetic Alliance Registry and Biobank. She is also the founding CEO of PXE International. She is co-PI of PCORnet’s Coordinating Center and the co-chair of the National Academy of Medicine Genomics and Health Roundtable. She led the coalition instrumental in passing the Genetic Information Nondiscrimination Act. She is a citizen scientist and advocate.
Matthew J. Thomas, ScM, CGC
Matthew is a pediatric and cardiovascular genetic counselor at University of Virginia Health System. From 2014 to 2017, he was chair of Virginia’s Advisory Board of Genetic Counselors. In 2013, he founded the first cardiovascular genetics program in the state.
Eliezer Van Allen, MD
Eliezer is an assistant professor of medicine at Harvard Medical School, a clinician at Dana-Farber/Partners Cancer Care and an associate member at the Broad Institute of MIT and Harvard. He is a computational biologist and medical oncologist whose research focuses on computational cancer genomics and applying new technologies to precision cancer medicine.
Catherine A. Wicklund, MS, CGC
Catherine is a director of the Graduate Program in Genetic Counseling at Northwestern University and associate professor in the Department of Obstetrics and Gynecology. She is past president of the National Society of Genetic Counselors (NSGC) and NSGC’s representative on the National Academies of Sciences, Engineering, Medicine Roundtable on Genomics and Precision Health. Ms. Wicklund’s expertise is in genetic counseling and genomic education, and her research interests include bringing personalized medicine into broader clinical use.
Backed by some of the strongest
World Class Investors
”The Genome Medical team’s vision and experience are unmatched. Their commitment to bringing genomic medicine into mainstream health care in a medically responsible way has the potential to transform the next chapter of medicine.Stephen BlochGeneral Partner, Canaan Partners